<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02036372</url>
  </required_header>
  <id_info>
    <org_study_id>NL 41467.018.12</org_study_id>
    <nct_id>NCT02036372</nct_id>
  </id_info>
  <brief_title>Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus</brief_title>
  <acronym>PILGRIM</acronym>
  <official_title>PILGRIM - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus Type II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of diabetes mellitus type II is increasing. More and more patients who need
      surgery have diabetes mellitus type II. Despite an enormous amount of glucose lowering
      protocols and the proven negative effects of hyperglycaemia. There is no evidence for the
      optimal glucose lowering protocol.

      This study investigates the optimal intraoperative treatment algorithm to lower glucose in
      patients with diabetes mellitus type 2 undergoing non-cardiac surgery, comparing
      intraoperative glucose-insulin-potassium infusion (GIK), insulin bolus regimen (BR) and GLP-1
      (liraglutide, LG) treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes mellitus is associated with poor outcome after surgery. The prevalence of diabetes
      in hospitalised patients is up to 40%, meaning that the anaesthesiologist will encounter a
      diabetes patient in the operating room on a daily basis. Multiple protocols for perioperative
      glucose regulation have been developed, ranging from intravenous glucose-insulin-potassium
      infusion to subcutaneous bolus regimens. Despite this abundance of published glucose lowering
      protocols and the proven negative effects of intraoperative hyperglycaemia in diabetes, there
      is no evidence regarding the optimal intraoperative glucose lowering treatment. Recently,
      incretins have been introduced to lower blood glucose. The main hormone of the incretin
      system is glucagon-like peptide-1 (GLP-1). GLP-1 increases insulin and decreases glucagon
      secretion in a glucose-dependent manner, resulting in low incidence of hypoglycaemia. This
      study investigates for the first time the optimal intraoperative treatment algorithm to lower
      glucose in patients with diabetes mellitus undergoing non-cardiac surgery.

      Objective:

      This study investigates the optimal intraoperative treatment algorithm to lower glucose in
      patients with diabetes mellitus type 2 undergoing non-cardiac surgery, comparing
      intraoperative glucose-insulin-potassium infusion (GIK), insulin bolus regimen (BR) and GLP-1
      (liraglutide, LG) treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median glucose</measure>
    <time_frame>1 hour after surgery</time_frame>
    <description>The difference in median glucose between the GIK + BR and LG group 1 hour after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Insulin administration</measure>
    <time_frame>1 day postoperative</time_frame>
    <description>The difference in insulin administration between the GIK + BR and LG group within 24 h after start of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median glucose</measure>
    <time_frame>4 hours and 1 day postoperative</time_frame>
    <description>The difference in median glucose between the GIK + BR and LG group 4 hours and 1 day after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative complications</measure>
    <time_frame>1 month after surgery</time_frame>
    <description>The difference in proportion of any postoperative complication within the first month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia</measure>
    <time_frame>From start treatment until the morning of day 1 postoperative</time_frame>
    <description>The occurrence of mild and severe hypoglycemia (glucose &lt;4.0 mmol/l and &lt;2.3 mmol/l, respectively) during and up to 24 h after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypo- and hyperkalemia</measure>
    <time_frame>from start treatment until morning of day 1 postoperative</time_frame>
    <description>The occurrence of hypokalemia (&lt;3.5 mmol/l) and hyperkalemia (&gt;5.0 mmol/l) during and up to 24 h after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>From start treatment until morning of day 1 postoperative</time_frame>
    <description>the difference in median glucose 1hr preoperative, 1, 4 hours postoperative, 1 day postoperative between the three groups.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Diabetes Mellitus Type II</condition>
  <arm_group>
    <arm_group_label>BR (bolus regimen)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day before surgery: half evening dose long acting insulin
Day of surgery:
patients using mealtime and longacting insulin/NPH: withhold mealtime morning dose, stop glucose lowering tablets
patients using only long acting insulin/NPH: half dose of long-acting or NPH insulin, stop glucose lowering tablets
Measure blood glucose every 60 minutes, start 30 min prior to surgery
Give bolus of insulin according to treatment algorithm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LG (Liraglutide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day before surgery: half dose of long acting and mealtime insulin from start liraglutide
Day of surgery: withhold own insulin, stop oral glucose lowering tablets
Start with 0.6 mg liraglutide subcutaneously (s.c.) the day prior to surgery at 17.00hr.
In case of nausea graded higher than minimal, the patient will be excluded from the study
Otherwise, treatment will be continued with 1.2 mg liraglutide s.c. per day on the day of surgery at 07.00hr.
Measure glucose every 60 minutes, start 30 min prior to surgery
Adjust according to bolus algorithm of BR group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIK (glucose -insulin - potassium) infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day before surgery: half evening dose long acting insulin
Day of surgery: stop oral glucose lowering tablets and withhold own insulin.
GIK infusion: 500 cc glucose 5% with insulin and 10 mmol KCL per 500 cc. Start at 83 ml/hr.
Calculate the insulin amount in the GIK infusion according to the formula:
I= (PG-7)/(200/W)+8 I=Insulin amount, PG=glucose 30 minutes preoperative, W= body weight in kg
Measure blood glucose every 60 minutes, start 30 min prior to surgery
Adjust glucose &gt; 8 mmol/l according to treatment algorithm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <arm_group_label>LG (Liraglutide)</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin bolus</intervention_name>
    <arm_group_label>BR (bolus regimen)</arm_group_label>
    <arm_group_label>LG (Liraglutide)</arm_group_label>
    <other_name>novorapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GIK infusion</intervention_name>
    <description>continuous infusion</description>
    <arm_group_label>GIK (glucose -insulin - potassium) infusion</arm_group_label>
    <other_name>glucose, insulin, potassium infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  known diabetes mellitus type II for &gt; 3 months

          -  aged 18-75 years

          -  scheduled for elective non-cardiac surgery

        Exclusion Criteria:

        - Daily insulin dosage of &gt; 1 IU/kg body weight

          -  Oral corticosteroid use

          -  Planned for day-care (ambulant) surgery

          -  Planned ICU stay post-operatively

          -  Planned bowel surgery

          -  History of chronic pancreatitis or idiopathic acute pancreatitis

          -  Impaired renal function defined as serum-creatinine ≥ 133 μmol/L for males and ≥ 115
             μmol/L for females

          -  Females of child bearing potential who are pregnant, breast-feeding or intend to
             become pregnant or are not using adequate contraceptive methods (adequate
             contraceptive measures as required by local law or practice)

          -  Known or suspected allergy to trial product(s) or related products

          -  Any condition that the local investigator feels would interfere with trial
             participation or the evaluation of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benedikt Preckel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academic Medical Centre - AMC-UvA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <state>Please Select</state>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <zip>3582 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://diapedia.org</url>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>B Preckel</investigator_full_name>
    <investigator_title>Prof dr B Preckel, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>glucose</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>perioperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

